Search clinical trials for: Pitavastatin, Valsartan

Total 724 results

Duke University
Novartis Pharmaceuticals

Completed

Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 (PARACOR-19)

Covid19

United States
RenJi Hospital

Unknown

Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD (EARLY-MYO-CTD)

Myocardial Injury | Connective Tissue Diseases

China
Oslo University Hospital

Unknown

Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

Heart Failure, Systolic

Norway
The Young Investigator Group of Cardiovascular...

Completed

The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction (RSVP-AMI)

Acute Myocardial Infarction

Egypt
Novartis
The TIMI Study Group

Completed

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Myocardial Ischemia | Post Acute Coronary Syndrome

Germany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
Juntendo University
Kumamoto University; Tokyo University; Kyoto University; Tohoku University; Yamaguchi...

Completed

Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)

Coronary Artery Disease

Japan
LG Life Sciences

Completed

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Hypertension

Korea, Republic of
Newcastle-upon-Tyne Hospitals NHS Trust
Assistance Publique - Hôpitaux de Paris; Azienda Ospedaliero-Universitaria... and other collaborators

Completed

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy (SILICOFCM)

Hypertrophic Cardiomyopathy

United Kingdom
Novartis Pharmaceuticals

Completed

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Heart Failure

United States
Clinision

Completed

Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients

Heart Failure NYHA Class II | Heart Failure NYHA Class IV

Pakistan
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Type II Hyperlipidemia

Netherlands
University of Zagreb

Active, not recruiting

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients (ENVAD-HF)

Heart Failure

Netherlands, Croatia, Poland, Czechia
Torbjorn Omland
Oslo University Hospital; Novartis; University Hospital of North Norway; Helse... and other collaborators

Active, not recruiting

Prevention of Cardiac Dysfunction During Breast Cancer Therapy (PRADAII)

Heart Failure | Breast Cancer Female

Norway
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE)

Chronic Heart Failure (CHF)

Spain, Croatia, Taiwan, Germany, Italy, United States, Australia, Netherlands, Switzerland, Belgium, United Kingdom, Bulgaria, Lithuania, Russian Federation, France, Argentina, Korea, Republic of, Poland, Canada, Turkey
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Yonsei University

Completed

Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia

Dyslipidemias

Korea, Republic of
Seoul National University Hospital
JW Pharmaceutical

Unknown

Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome

Metabolic Syndrome

Korea, Republic of
Ziekenhuis Oost-Limburg
Jessa Hospital

Recruiting

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation (PRAISE-MR)

Heart Failure With Preserved Ejection Fraction | Functional Mitral Regurgitation

Belgium
Shenzhen Second People's Hospital

Recruiting

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Heart Failure | Hemodialysis Complication | Peritoneal Dialysis Complication

China
Horng Chen

Enrolling by invitation

Enhancing the Natriuretic Peptide System in HFpEF

Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Germans Trias i Pujol Hospital

Completed

Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device (ARNIMEMS-HFpEF)

Pulmonary Hypertension

Spain
University Hospital, Montpellier

Completed

Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study (ENTRESTO696)

Chronic Heart Failure | Sleep Apnea Syndrome

France
Novartis Pharmaceuticals

Completed

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. (PIONEER-HF)

Acute Heart Failure

United States
Novartis Pharmaceuticals

Completed

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. (AWAKE-HF)

Heart Failure, Reduced Ejection Fraction

United States
Sun Yat-sen University

Completed

Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

Renal Function Disorder

China
Novartis

Completed

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Proteinuria | Microalbuminuria

Egypt
Novartis

Completed

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Diastolic Dysfunction, Symptomatic Heart Failure

Switzerland, Germany
Kumamoto University

Terminated

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Hypertension

Japan
Novartis

Completed

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

Hypertension

Germany
Novartis

Completed

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Hypertension

Switzerland
Samsung Medical Center

Unknown

The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

Proteinuria | Chronic Kidney Disease

Korea, Republic of
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Jikei University School of Medicine

Unknown

A Morbidity-Mortality and Remodeling Study With Valsartan

Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
Instituto de Investigación Hospital Universitario...
Instituto de Salud Carlos III

Not yet recruiting

Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins (PREVESTATGx)

Cardiovascular Diseases | Dyslipidemias | Statin Adverse Reaction | Pharmacogenic Myopathy

Spain
National Heart Centre Singapore
National Medical Research Council (NMRC), Singapore

Recruiting

Role of ARNi in Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH)

Hypertensive Heart Disease

Singapore
Newcastle University
University of Belgrade; Azienda Ospedaliero-Universitaria Careggi; University... and other collaborators

Completed

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy (SILICOFCM)

Hypertrophic Cardiomyopathy

Germany, Italy, Serbia, United Kingdom
National Institute of Cardiovascular Diseases,...

Completed

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Heart Failure, Systolic

Pakistan
Massachusetts General Hospital

Recruiting

Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)

HIV/AIDS | Heart Failure With Preserved Ejection Fraction

United States
Novartis

Completed

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Hypertension | Type 2 Diabetes | PROTEINURIA
Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Novartis Pharmaceuticals

Completed

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Hypertension | Chronic Kidney Disease | Nephrotic Syndrome

Japan
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Hypertension

United States
Wake Forest University Health Sciences
Johns Hopkins University

Terminated

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients (RAS-HIV)

HIV | Sarcopenia | Aging | Angiotensin Receptor Antagonists

United States
The Affiliated Hospital of Qingdao University

Recruiting

Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

Cardio-Renal Syndrome

China
Montreal Heart Institute
Novartis Pharmaceuticals

Terminated

ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure (PARACYS-RV)

Heart Failure | Systemic Right Ventricle

Canada
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension

Hypertension

China
Novartis Pharmaceuticals

Completed

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure (OUTSTEP-HF)

Chronic Heart Failure With Reduced Ejection Fraction

Belgium, Estonia, Denmark, Greece, United Kingdom, Germany, Latvia, Lithuania, Spain, Netherlands, Bulgaria, Finland, Poland, Czechia, Iceland, Sweden, France, Ireland, Norway
Emmaus Medical, Inc.

Completed

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

Sickle Cell Disease | Pharmacokinetics

United States

Search clinical trials for: Pitavastatin, Valsartan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations